WINTON GROUP Ltd Acquires 1,274 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

WINTON GROUP Ltd grew its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 24.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,565 shares of the company’s stock after purchasing an additional 1,274 shares during the period. WINTON GROUP Ltd’s holdings in Krystal Biotech were worth $1,028,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of KRYS. Wilmington Savings Fund Society FSB purchased a new position in Krystal Biotech during the 3rd quarter valued at about $40,000. Avanza Fonder AB bought a new position in shares of Krystal Biotech in the fourth quarter valued at approximately $119,000. KBC Group NV grew its stake in Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after acquiring an additional 297 shares in the last quarter. Blue Trust Inc. increased its holdings in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after acquiring an additional 433 shares during the period. Finally, US Bancorp DE lifted its stake in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after purchasing an additional 82 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital boosted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price on the stock. Finally, Citigroup boosted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $220.00.

Insider Activity

In related news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Krystal Biotech Price Performance

Shares of KRYS opened at $183.92 on Friday. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34. The stock has a 50 day simple moving average of $170.82 and a two-hundred day simple moving average of $173.73. The firm has a market cap of $5.30 billion, a P/E ratio of 61.51 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm’s quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.30 EPS. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).